Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2018-02-16 Regulatory Filings
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure Announces U.S. FDA Approval of New Indications for Blue Light Cystoscopy with Cysview®
Regulatory Filings Classification · 100% confidence The document is a press release titled "Photocure Announces U.S. FDA Approval of New Indications for Blue Light Cystoscopy with Cysview®". It details a specific regulatory event (FDA approval) and its implications for the company's product. This type of announcement, which communicates significant corporate news, regulatory milestones, or financial updates outside of the mandatory periodic reports (like 10-K or IR), typically falls under a general regulatory announcement or earnings/news release category. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change (MANG), it is best classified as an Earnings Release (ER) if it contained financial results, or a general Regulatory Filing (RNS) if it is purely news. Given the content is a major product/regulatory milestone announcement, and it is not explicitly an Earnings Release (ER) which usually focuses on P&L/Balance Sheet figures, the most appropriate general category for significant, non-periodic corporate news is Regulatory Filings (RNS), as it is a formal announcement to the market about a regulatory event. However, since it is a major announcement of a business development/approval, and not just a miscellaneous filing, and it is not short enough to be an RPA, RNS serves as the best fit among the provided options for a significant, non-periodic corporate news release.
2018-02-16 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document text is titled 'Financial calendar' and lists scheduled dates for future corporate events, specifically 'Quarterly Report - Q4', 'Annual General Meeting', and 'Half-yearly Report' releases for 2017 and 2018. It is not the report itself, but an announcement about the schedule of future reports and meetings. Since it announces the timing/release of reports, the most appropriate classification is Report Publication Announcement (RPA). The document length is very short (531 chars), supporting the idea that it is an announcement rather than the full report.
2018-01-30 English
Photocure to present at investor meetings in San Francisco
Investor Presentation Classification · 99% confidence The document is explicitly titled "PHOTOCURE ASA CORPORATE PRESENTATION" and contains detailed slides covering company background, investment highlights, product information (Hexvix®/Cysview®), market statistics, clinical evidence, sales execution plans, and future opportunities. This structure is characteristic of a presentation designed to inform current and potential investors about the company's strategy, performance, and outlook. This aligns perfectly with the definition of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a transcript (CT).
2018-01-08 English
Photocure to present at investor meetings in San Francisco
Investor Presentation Classification · 95% confidence The document is very short (973 characters) and announces that management will be conducting investor meetings and that the 'presentation [is] attached'. This structure strongly suggests an announcement about an upcoming event or the availability of presentation materials, rather than the presentation itself or a formal regulatory filing like a 10-K or IR. Since the document explicitly mentions a presentation being attached for investor meetings, the most appropriate classification is Investor Presentation (IP). However, given the 'MENU VS MEAL' rule, if this is merely an announcement stating the presentation is attached, it could also be a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the content is specifically about an Investor Presentation being made available in connection with investor meetings, IP is the most specific fit, assuming the attached document is the presentation itself. If the text *is* the presentation, IP is correct. If the text is just a short notice *about* the presentation, RPA might apply. Given the context of 'investor meetings' and 'presentation attached', IP is the primary intent. I will classify it as IP.
2018-01-08 English
Photocure ASA: Presentation at the DNB Nordic Healthcare Conference, Oslo
Investor Presentation Classification · 95% confidence The document is a short announcement (1364 characters) stating that Photocure ASA will present at the DNB Nordic Healthcare Conference on December 14, 2017, and that the presentation slides will be made available on their website. This fits the definition of an announcement regarding an upcoming presentation or event, which is best categorized as an Investor Presentation (IP) announcement or, given the context of a conference presentation, potentially an AGM-R if it were an AGM, but since it's a third-party conference, it's an Investor Presentation (IP) or a general Regulatory Filing (RNS). Since the document explicitly mentions the presentation slides will be available, and it is an announcement about participation in an investor-focused conference, 'Investor Presentation' (IP) is the most specific fit, even though it's an announcement *about* the presentation rather than the presentation itself. However, given the options, and the nature of conference presentations being investor-facing materials, IP is strong. If we strictly follow the 'MENU VS MEAL' rule, since it's an announcement that the slides *will be available*, it could be RPA or RNS. Given that the content is about an investor conference presentation, IP is the most descriptive category for the *subject matter*. Let's re-evaluate against the definitions. It is not a formal AGM (AGM-R), nor is it a full report (10-K, IR). It is an announcement of participation in a conference where investor materials will be shared. This aligns closely with the spirit of an Investor Presentation (IP). If the slides were attached, it would be IP. Since it's an announcement *about* the presentation, and it's not a general regulatory filing (RNS) or a report publication announcement (RPA) for a statutory report, IP remains the most relevant subject classification for investor relations materials.
2017-12-13 English
Photocure ASA: Landmark Blue Light Cystoscopy with Cysview® study is published in the Journal of Urology
Regulatory Filings Classification · 95% confidence The document is a press release from Photocure ASA dated December 8, 2017, announcing that the efficacy results of a Phase 3 trial for their product Cysview® were published in the Journal of Urology. This type of announcement, which details the publication of study results or regulatory submissions without being the full report itself, typically falls under a general regulatory announcement or a specific type of corporate communication. Since it is an announcement about a published study/data, it is not a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is not a Call Transcript (CT), Director's Dealing (DIRS), or Dividend Notice (DIV). Given the content is a formal announcement regarding a significant development (publication of clinical trial data), and it doesn't fit the specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate general category for significant, non-standard regulatory/corporate news is Regulatory Filings (RNS), as it serves as a broad announcement mechanism for material information not covered by other specific codes. It is not an RPA because it is announcing the publication of a study, not the publication of one of the company's own periodic reports (like a 10-K or IR). Therefore, RNS is the best fit.
2017-12-08 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.